Skip to content
Business
Prognosis

Moderna Gains as RSV Shot Prevents Most Cases in Older People

  • Shot prevents about 84% of mild RSV cases, 82% of severe cases
  • Company may use voucher for expedited FDA review, CEO says
A healthcare worker prepares Moderna Inc. vaccines in Tokyo.

A healthcare worker prepares Moderna Inc. vaccines in Tokyo.

Photographer: Toru Hanai/Bloomberg
Updated on

Moderna Inc.’s vaccine against RSV was highly effective in preventing the lung disease in older people, paving the way for the company to seek its first approval outside Covid-19. 

The shot blocked about 84% of mild respiratory syncytial virus infections and 82% of severe cases in a Phase 3 study, Cambridge, Massachusetts-based Moderna said Tuesday. Results from the study of about 37,000 volunteers 60 and older, which is continuing to collect data, will be published and presented at a later date, the company said.